The benefits and risks of systemic corticosteroids in the treatment of IgA nephropathy are still controversial. Part A results of the Efficacy and Safety of Nefecon in Patients With Primary IgA Nephropathy (NefIgArd) trial provide significant effects on decrease in proteinuria and protection from estimated glomerular filtration rate decline after 9 months of treatment with budesonide (Nefecon). Targeting the initiating pathogenetic event in the gut-associated lymphoid tissue would offer a and possible multiple effects of this treatment are critically discussed.
机构:
Hong Kong Sanat & Hosp, Nephrol Ctr, 10-F Li Shu Pui Bldg, Happy Valley, Hong Kong, Peoples R China
Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R ChinaHong Kong Sanat & Hosp, Nephrol Ctr, 10-F Li Shu Pui Bldg, Happy Valley, Hong Kong, Peoples R China
Lai, Kar Neng
Leung, Joseph C. K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R ChinaHong Kong Sanat & Hosp, Nephrol Ctr, 10-F Li Shu Pui Bldg, Happy Valley, Hong Kong, Peoples R China
Leung, Joseph C. K.
Tang, Sydney C. W.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R ChinaHong Kong Sanat & Hosp, Nephrol Ctr, 10-F Li Shu Pui Bldg, Happy Valley, Hong Kong, Peoples R China